Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | August 2010 |
| End Date: | July 2012 |
| Contact: | Linda Rose, MD |
| Email: | lirose@salud.unm.edu |
| Phone: | 505-272-6120 |
The Use of Ranibizumab to Control Pterygium Growth in Recurrences and in Non-surgical Primary Lesions.
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in
pterygium, a neovascular disorder of the ocular surface.
pterygium, a neovascular disorder of the ocular surface.
Ptergyia are chronic fibrovascular lesions of the ocular surface. This study is designed to
look for a signal of efficacy when the lesions are in a phase of active vascular growth.
This phase is most often caught in a newly recurring pterygia post-operatively.
Patients identified with actively growing lesions, will be offered local injections directly
beneath the lesions. They will be examined for any adverse side effects and regression of
the lesion.
look for a signal of efficacy when the lesions are in a phase of active vascular growth.
This phase is most often caught in a newly recurring pterygia post-operatively.
Patients identified with actively growing lesions, will be offered local injections directly
beneath the lesions. They will be examined for any adverse side effects and regression of
the lesion.
Inclusion Criteria:
Patients with actively growing pterygia, either surgical recurrences, or non-surgical
primary lesions.
Exclusion Criteria:
- Pregnancy
- History of CVA
- Monocular patients
- Minors
We found this trial at
1
site
Click here to add this to my saved trials
